Friday, February 01, 2019 6:22:45 PM
No FDA trial even started. Their application has not even been approved. No product marketing claims can be made to physicians until they are proven in an FDA study. The study process and acceptance will take YEARS. The outcome may not be positive. WAY before then they will run out of money and need to issue many more shares to keep hobbling along. That means share price dilution. I see them at a billion shares outstanding in the next 2 years and the price will be like 2-3c. Maybe its a speculative buy then if the FDA trials work out.
Bottom line is this is a sell at the current high price of 8c a share. More money will need to be raised and they will have a hard time even getting 8c a share. My guess is potential future private placements at 2c a share. Sell now maybe keep an eye on it every 6 mos or so and if it is still around in 2 years and they have FDA approval and a product then just maybe its a buy. In my opinion!
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM